Foundation Fighting Blindness Fnd Fighting Blindness

Dr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in people with retinitis pigmentosa. The powerful antioxidant has moved into a 30+ site, Phase 3 clinical trial called NAC Attack.

Peter Wallsten, a veteran newspaper journalist and head of investigative reporting at The Washington Post, talks to host Ben Shaberman about his evolving career as a reporter and editor and the impact that Stargardt disease has had on his journey and ambitions. Peter also reflects on recently receiving a Pulitzer Prize for his team's 15-part series on the role of the AR-15 assault rifle in mass shootings and how the weapon has become one of the best-selling firearms in the US.

The emerging treatment is designed to work for people with RP and other conditions regardless of the gene mutation causing disease

No serious adverse events were reported. One patient had encouraging improvement in retinal sensitivity.

The discovery will help geneticists diagnose more RP patients with African descent.

Mutations in PDE6B are a leading cause of retinitis pigmentosa.